Meiragtx holdings plc MGTX.US Overview
MGTX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
MGTX Current Performance
-3.71%
Meiragtx holdings plc
-1.83%
Avg of Sector
-0.40%
S&P500
MGTX Key Information
MGTX Revenue by Segments
Browsing restrictions can be lifted for a fee.
MGTX Net Income
Browsing restrictions can be lifted for a fee.
MGTX Cash Flow
Browsing restrictions can be lifted for a fee.
MGTX Profit Margin
Browsing restrictions can be lifted for a fee.
MGTX PE Ratio River
Browsing restrictions can be lifted for a fee.
MGTX Financial Forecast
Browsing restrictions can be lifted for a fee.
MGTX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
MGTX Profile
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Price of MGTX
MGTX FAQ
When is MGTX's latest earnings report released?
The most recent financial report for Meiragtx holdings plc (MGTX) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MGTX's short-term business performance and financial health. For the latest updates on MGTX's earnings releases, visit this page regularly.
What is the operating profit of MGTX?
According to the latest financial report, Meiragtx holdings plc (MGTX) reported an Operating Profit of -41.6M with an Operating Margin of -2,159.71% this period, representing a growth of 11.07% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is MGTX's revenue growth?
In the latest financial report, Meiragtx holdings plc (MGTX) announced revenue of 1.93M, with a Year-Over-Year growth rate of 176.33%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does MGTX have?
As of the end of the reporting period, Meiragtx holdings plc (MGTX) had total debt of 80.88M, with a debt ratio of 0.36. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does MGTX have?
At the end of the period, Meiragtx holdings plc (MGTX) held Total Cash and Cash Equivalents of 68.61M, accounting for 0.31 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does MGTX go with three margins increasing?
In the latest report, Meiragtx holdings plc (MGTX) did not achieve the “three margins increasing” benchmark, with a gross margin of 28.5%%, operating margin of -2,159.71%%, and net margin of -2,075.9%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MGTX's profit trajectory and future growth potential.
Is MGTX's EPS continuing to grow?
According to the past four quarterly reports, Meiragtx holdings plc (MGTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.51. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of MGTX?
Meiragtx holdings plc (MGTX)'s Free Cash Flow (FCF) for the period is -38.54M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 309.94% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of MGTX?
The latest valuation data shows Meiragtx holdings plc (MGTX) has a Price-To-Earnings (PE) ratio of -2.47 and a Price/Earnings-To-Growth (PEG) ratio of -0.82. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.